<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Hadjipaschali, E.</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J EpidemiolEur J EpidemiolEur J Epidemiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">European journal of epidemiology</style></alt-title><short-title><style face="normal" font="default" size="100%">European journal of epidemiologyEuropean journal of epidemiology</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style  face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style  face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece/epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B Antibodies/blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B Surface Antigens/blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B/*diagnosis/epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C Antibodies/blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C/*diagnosis/epidemiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoenzyme Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mass Screening</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Occupational Health Services/*organization &amp; administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Program Evaluation</style></keyword><keyword><style  face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">721-8</style></pages><isbn><style face="normal" font="default" size="100%">0393-2990 (Print)0393-2990 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">A cross-sectional study was carried out in employees of 17 Greek companies with the aim of assessing the prevalence of hepatitis B (HBV) and hepatitis C (HCV) virus, identifying associated prognostic/risk factors and evaluating the effectiveness of a questionnaire as a pre-screening tool. All participants were asked to complete a questionnaire and a random sample of them was asked to provide a blood sample for hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and antibodies to hepatitis C (anti-HCV) testing. Individual questions or combinations of them were evaluated in terms of their ability to detect HBV or HCV(+) cases. Of 9085 eligible employees, 6074 (67%) completed the questionnaire. Of 990 samples obtained, 19.9% were anti-HBc(+), 2.6% HBsAg(+) and 0.5% anti-HCV(+). All anti-HCV(+) cases had multiple parenteral risk factors. Multiple logistic regression identified associations between anti-HBc and older age, family members with chronic hepatitis, job category and history of transfusion before 1992. HBsAg(+) was associated with older age and history of transfusion before 1992. None of the risk/prognostic factors had sufficient sensitivity and specificity for HBV but report of at least one risk factor identified all HCV(+) cases. Anti-HCV screening of those with at least two parenteral risk factors not only identified all anti-HCV(+) cases but also resulted in 86% decrease in the screening cost. Under the light of recent treatment advances, targeted questionnaire-based screening of asymptomatic people may prove to be a cost-effective way to face hepatitis C.</style></abstract><accession-num><style face="normal" font="default" size="100%">12086089</style></accession-num><notes><style face="normal" font="default" size="100%">Sypsa, VHadjipaschali, EHatzakis, AengNetherlands2002/06/28 10:00Eur J Epidemiol. 2001;17(8):721-8. doi: 10.1023/a:1015671627577.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Hygiene and Epidemiology, Athens University Medical School, Greece.</style></auth-address></record></records></xml>